Real-world safety, dose reduction determinants, and effectiveness of first-line osimertinib in EGFR -mutated non-small-cell lung cancer: a single-center retrospective cohort study

JAAD International · Elsevier

Аннотация

Publication date: September 2026 Source: International Journal of Lung Cancer, Volume 1, Issue 3 Author(s): Yuya Murase, Kazuhiko Shibata, Keiichi Iwasa, Yasutaka Shiba, Junya Suzuki, Satoshi Tanaka, Akihito Bando, Yukari Nakagawa, Naoya Tachimura, Seiji Yano

Читать у издателя →

Похожие статьи